MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis.
Humans
Proto-Oncogene Proteins c-akt
/ metabolism
Down-Regulation
/ genetics
Cell Line, Tumor
MicroRNAs
/ genetics
Colorectal Neoplasms
/ pathology
Colonic Neoplasms
/ genetics
Transcription Factors
/ metabolism
Rectal Neoplasms
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
Cell Movement
/ genetics
Neoplasm Invasiveness
/ genetics
ERBB3
NDRG1
cancer stem cell
colorectal cancer
metastasis
miRNA-483-3p
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
07
02
2023
received:
04
11
2022
accepted:
27
02
2023
medline:
7
7
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
In colorectal cancer, the mechanisms underlying tumor aggressiveness require further elucidation. Taking advantage of a large panel of human metastatic colorectal cancer xenografts and matched stem-like cell cultures (m-colospheres), here we show that the overexpression of microRNA 483-3p (miRNA-483-3p; also known as MIR-483-3p), encoded by a frequently amplified gene locus, confers an aggressive phenotype. In m-colospheres, endogenous or ectopic miRNA-483-3p overexpression increased proliferative response, invasiveness, stem cell frequency, and resistance to differentiation. Transcriptomic analyses and functional validation found that miRNA-483-3p directly targets NDRG1, known as a metastasis suppressor involved in EGFR family downregulation. Mechanistically, miRNA-483-3p overexpression induced the signaling pathway triggered by ERBB3, including AKT and GSK3β, and led to the activation of transcription factors regulating epithelial-mesenchymal transition (EMT). Consistently, treatment with selective anti-ERBB3 antibodies counteracted the invasive growth of miRNA-483-3p-overexpressing m-colospheres. In human colorectal tumors, miRNA-483-3p expression inversely correlated with NDRG1 and directly correlated with EMT transcription factor expression and poor prognosis. These results unveil a previously unrecognized link between miRNA-483-3p, NDRG1, and ERBB3-AKT signaling that can directly support colorectal cancer invasion and is amenable to therapeutic targeting.
Identifiants
pubmed: 36862005
doi: 10.1002/1878-0261.13408
pmc: PMC10323897
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
MicroRNAs
0
Transcription Factors
0
MIRN483 microRNA, human
0
Banques de données
RefSeq
['NM_001374847.1']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1280-1301Subventions
Organisme : Cancer Research UK
ID : A28223
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A26825
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Biol Chem. 2017 Aug 4;292(31):12772-12782
pubmed: 28615452
Cell Stem Cell. 2011 Oct 4;9(4):357-65
pubmed: 21982235
Trends Biochem Sci. 2019 Aug;44(8):688-700
pubmed: 31085088
Cancer Res. 2017 Jan 1;77(1):86-99
pubmed: 27793840
Nat Rev Cancer. 2012 Jul 12;12(8):553-63
pubmed: 22785351
Nat Med. 2014 Jul;20(7):769-77
pubmed: 24859528
Nature. 2011 Jan 20;469(7330):415-8
pubmed: 21113151
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Cell Biol. 2004 Oct;6(10):931-40
pubmed: 15448698
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Cell Rep. 2021 Jul 27;36(4):109455
pubmed: 34320350
Cell Stem Cell. 2014 Mar 6;14(3):306-21
pubmed: 24607405
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Oncogene. 2008 Jan 3;27(1):107-15
pubmed: 17599044
Clin Cancer Res. 2018 Feb 15;24(4):807-820
pubmed: 28974546
Mol Syst Biol. 2005;1:2005.0008
pubmed: 16729043
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
pubmed: 12615961
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Cancer Discov. 2021 Jul;11(7):1644-1660
pubmed: 33820776
Nat Genet. 2017 Jan;49(1):65-74
pubmed: 27869826
Nature. 2015 Sep 24;525(7570):469-78
pubmed: 26399828
Cancer Res. 2010 Apr 15;70(8):3140-9
pubmed: 20388800
Oncogene. 2019 Jan;38(5):699-715
pubmed: 30171257
Oncogene. 2014 Jun 12;33(24):3172-82
pubmed: 23851495
J Vis Exp. 2015 Nov 20;(105):
pubmed: 26649463
Sci Transl Med. 2015 Jan 28;7(272):272ra12
pubmed: 25632036
Biochim Biophys Acta. 2014 Jan;1845(1):1-19
pubmed: 24269900
Science. 2003 Mar 14;299(5613):1753-5
pubmed: 12637750
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Genes Dev. 2021 Jun;35(11-12):787-820
pubmed: 34074695
Cancer Res. 2014 Mar 15;74(6):1857-69
pubmed: 24448239
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32
pubmed: 18765800
J Biol Chem. 2016 Jan 15;291(3):1029-52
pubmed: 26534963
Mol Cell Biol. 2001 Dec;21(23):8189-96
pubmed: 11689707
Free Radic Biol Med. 2020 Sep;157:154-175
pubmed: 31132412
PLoS One. 2008 Aug 06;3(8):e2888
pubmed: 18682804
Nat Commun. 2013;4:2956
pubmed: 24356439
Nat Rev Cancer. 2005 Sep;5(9):744-9
pubmed: 16148886
NPJ Syst Biol Appl. 2017 Jan 05;3:16034
pubmed: 28725482
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Cell Stem Cell. 2016 Dec 1;19(6):725-737
pubmed: 27641305
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Nat Rev Cancer. 2021 May;21(5):325-338
pubmed: 33547455
Cancer Res. 2000 Feb 1;60(3):749-55
pubmed: 10676663
Oncogene. 2021 Oct;40(41):5993-6006
pubmed: 34385595
Nat Commun. 2021 May 3;12(1):2498
pubmed: 33941777
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Mod Pathol. 2007 Dec;20(12):1286-97
pubmed: 17906616
Clin Cancer Res. 2009 Jul 15;15(14):4665-73
pubmed: 19584150